

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-67618-07
	Application Number	10/563,683
	Filing Date	October 4, 2006
	First Named Inventor	Gladwin
	Art Unit	1616
	Examiner Name	Anna Pagonakis

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date and submit a copy.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
/A.P./		3,865,942	02/11/1975	Wirth
		4,163,790	08/07/1979	Franko <i>et al.</i>
		4,211,782	07/08/1980	Vane <i>et al.</i>
		4,849,226	07/18/1989	Gale
		5,263,473	11/23/1993	McWhorter
		5,366,997	11/22/1994	Keefer <i>et al.</i>
		5,389,675	02/14/1995	Christodoulou <i>et al.</i>
		5,396,882	03/14/1995	Zapol
		5,427,797	06/27/1995	Frostell <i>et al.</i>
		5,525,357	06/11/1996	Keefer <i>et al.</i>
		5,536,241	07/16/1996	Zapol
		5,500,230	03/19/1996	Nathanson
		5,570,683	11/05/1996	Zapol
		5,650,442	07/22/1997	Mitchell <i>et al.</i>
		5,683,668	11/04/1997	Hrabie <i>et al.</i>
↓		5,814,666	09/29/1998	Green <i>et al.</i>
/A.P./		5,814,667	09/29/1998	Mitchell <i>et al.</i>

EXAMINER SIGNATURE:	/Anna Pagonakis/	DATE CONSIDERED:	09/25/2008
------------------------	------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-67618-07
	Application Number	10/563,683
	Filing Date	October 4, 2006
	First Named Inventor	Gladwin
	Art Unit	1616
	Examiner Name	Anna Pagonakis

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date and submit a copy.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
/A.P./		5,823,180	10/20/1998	Zapol
		5,837,736	11/17/1998	Mitchell <i>et al.</i>
		5,839,433	11/24/1998	Higenbottam
		5,840,759	11/24/1998	Mitchell <i>et al.</i>
		5,904,938	05/18/1999	Zapol <i>et al.</i>
		5,958,427	09/28/1999	Salzman <i>et al.</i>
		5,968,911	10/19/1999	Lawson <i>et al.</i>
		6,063,407	05/16/2000	Zapol <i>et al.</i>
		6,187,332	02/13/2001	Gern <i>et al.</i>
		6,197,762	03/06/2001	Garvey <i>et al.</i>
		6,277,891	08/21/2001	Sanders <i>et al.</i>
		6,391,895	05/21/2002	Towart <i>et al.</i>
		6,476,037	11/05/2002	Wallace
		6,601,580	08/05/2003	Bloch <i>et al.</i>
		6,656,452	12/02/2003	Zapol <i>et al.</i>
↓		6,709,681	03/23/2004	Benjamin <i>et al.</i>
/A.P./		6,723,703	04/20/2004	Gaston <i>et al.</i>

EXAMINER SIGNATURE:	/Anna Pagonakis/	DATE CONSIDERED:
------------------------	------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67618-07
		Application Number	10/563,683
		Filing Date	October 4, 2006
		First Named Inventor	Gladwin
		Art Unit	1616
		Examiner Name	Anna Pagonakis

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date and submit a copy.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
/A.P./		6,811,768	11/02/2004	Zapol <i>et al.</i>
		6,935,334	08/30/2005	Bloch <i>et al.</i>
		6,945,247	09/20/2005	Stamler <i>et al.</i>
		7,040,313	05/09/2006	Fine <i>et al.</i>
		7,048,951	05/23/2006	Seitz <i>et al.</i>
		7,335,181	02/26/2008	Miller <i>et al.</i>
		US2002/0151597	10/17/2002	Banerjee <i>et al.</i>
		US2002/0155174	10/24/2002	Benjamin <i>et al.</i>
		US2003/0032917	02/13/2003	Stamler
		US2004/0037897	02/26/2004	Benjamin <i>et al.</i>
		US2004/0105898	06/03/2004	Benjamin <i>et al.</i>
		US2005/0036949	02/17/2005	Tucker <i>et al.</i>
		US2005/0037093	02/17/2005	Benjamin
		US2005/0069595	03/31/2005	Chen <i>et al.</i>
		US2005/0131064	06/15/2005	Gaston <i>et al.</i>
↓		US2006/0147553	07/06/2006	Miller <i>et al.</i>
/A.P./		US2006/0182815	08/17/2006	Gladwin <i>et al.</i>

EXAMINER SIGNATURE:	/Anna Pagonakis/	DATE CONSIDERED:	09/25/2008
------------------------	------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-67618-07
	Application Number	10/563,683
	Filing Date	October 4, 2006
	First Named Inventor	Gladwin
	Art Unit	1616
	Examiner Name	Anna Pagonakis

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date and submit a copy.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patente
/A.P./		US2007/0086954	04/19/2007	Miller
/A.P./		US2007/0144515	06/28/2007	Stenzler <i>et al.</i>
/A.P./		US2007/0190184	08/16/2007	Montgomery <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patente
/A.P./		WO	94/00180	01/06/1994	The General Hospital Corporation
		WO	95/022335	08/24/1995	Aberdeen University
		WO	99/002148	01/21/1999	The Johns Hopkins University School of Medicine
		WO	99/038472	08/05/1999	Seatrace Pharmaceuticals, Inc.
		WO	99/044622	09/10/1999	Aberdeen University
		WO	00/30659	06/02/2000	Pulmonox Medical Corporation
		WO	01/010406	02/15/2001	Board of Regents, The University of Texas System
		WO	01/043805	06/21/2001	Ino Therapeutics GmbH
		WO	01/089572	11/29/2001	Nitric Oxide Solutions
↓		WO	01/80890	11/01/2001	Queen's University at Kingston
/A.P./		WO	02/020026	03/14/2002	Aberdeen University

EXAMINER /Anna Pagonakis/ SIGNATURE:	DATE CONSIDERED:
---	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-67618-07
	Application Number	10/563,683
	Filing Date	October 4, 2006
	First Named Inventor	Gladwin
	Art Unit	1616
	Examiner Name	Anna Pagonakis

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/A.P./		WO	02/17898	03/07/2002	Sacks

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Other Documents
/A.P./		Butler <i>et al.</i> , "Therapeutic Uses of Inorganic Nitrite and Nitrate: From the Past to the Future," <i>Circulation</i> , 117:2151-2159 (2008)
/A.P./		Duriez <i>et al.</i> , "A Common Variant in Combination with a Nonsense Mutation in a Member of the Thioredoxin Family Causes Primary Ciliary Dyskinesia," <i>PNAS</i> , 104:3336-3341 (2007)
/A.P./		Furchtgott <i>et al.</i> , "Reactions of Strips of Rabbit Aorta to Epinephrine, Isopropylarterenol, Sodium Nitrite and Other Drugs," <i>J Pharmacol Exp Ther</i> , 108:129-143 (1952)
/A.P./		Isbell <i>et al.</i> , "Hemoglobin Oxygen fractional saturation regulates nitrite-dependent vasodilation of aortic ring bioassays," <i>Am J Physiol Heart Circ Physiol</i> , 293:H2565-H2572 (2007)
/A.P./		Lyra and Diniz, "The Importance of Surfactant on the Development of Neonatal Pulmonary Diseases," <i>Clinics</i> , 62:181-190 (2007)
/A.P./		McMahon <i>et al.</i> , "Nitric Oxide in the Human Respiratory Cycle," <i>Nature Medicine</i> , 8(7):711-717 (2002)
/A.P./		Pawloski <i>et al.</i> , "Export by Red Blood Cells of Nitric Oxide Bioactivity," <i>Nature</i> , 409:622-626 (2001)

EXAMINER SIGNATURE:	/Anna Pagonakis/	DATE CONSIDERED:	09/25/2008
------------------------	------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.